Ligand Pharmaceuticals Inc.
- BID
264
- ASK
268
- 110 Units109 Units
- 07/24, 12:03:32 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
129.57%
Market Cap
-
P/E Ratio
30.83
Dividend Yield
0.00 %
Earnings per Share
5.44 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 264 G | 0 Units |
| PRICE DETERMINATION TIME | 07/24/2026 / 12:03:23 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 264 | 262 |
| PREV. DAY'S PRICE | 264 | (07/23) |
| CHANGE DAY BEFORE | +0.00 | 0.00 % |
| 52 WEEK HIGH / LOW | 286 (07/01) | 112 (07/24) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 2.72 | -0.20 | 5.44 | 8.01 | 10.22 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 24.32 | - | 30.83 | 33.42 | 26.20 |
PRICE - BOOK RATIO | 1.79 | 2.47 | 3.68 | - | - |
PRICE - SALES RATIO | 9.66 | 11.73 | 14.31 | - | - |
PRICE - CASH FLOW RATIO | 26.08 | 20.28 | 77.74 | - | - |
Master Data
| WKN | A1C9RN |
| ISIN | US53220K5048 |
| SYMBOL | LGDN |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | LIGAND PHARMAC.NEW DL-001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.33 % | 8.20 % | 36.08 % | 57.14 % | 129.57 % | 336.36 % | 200.09 % | 61.96 % |
| HIGH | 270.00 | 286.00 | 286.00 | 286.00 | 286.00 | 286.00 | 286.00 | 286.00 |
| LOW | 252.00 | 240.00 | 175.00 | 150.00 | 112.00 | 46.40 | 46.40 | 150.00 |
Dividende
pro Aktie
LIGAND PHARMAC.NEW DL-001 does not deliver dividend information
Company profile
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Structured products for Ligand Pharmaceuticals Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.